Can Enasidenib completely cure related diseases?

Enasidenib is an oral targeted drug targeting isocitrate dehydrogenase 2 (IDH2) mutations. It is mainly used to treat patients with relapsed or refractory acute myeloid leukemia (AML). Its mechanism is based on inhibiting the function of IDH2 mutant enzyme, thereby reducing 2-hydroxyglutarate (2-HG) levels and restoring normal differentiation of blood cells. In clinical application, ensidipine can significantly improve hematopoietic functions such as hemoglobin, platelets, and white blood cells, and induce complete remission in some patients, which is its greatest therapeutic advantage. However, judging from global clinical practice and research results, ensidipine is not a “curative drug” in the traditional sense. Its goal is more to achieve disease remission and long-term control rather than to completely cure AML.

AML is a highly heterogeneous hematological malignant tumor. Its pathogenesis involves abnormalities in multiple genes and signaling pathways. All lesions cannot be eliminated by targeting IDH2 mutations alone. Ensidipine can effectively inhibit differentiation disorders mediated by IDH2 mutations and restore hematological indicators to normal in some patients, but residual clonal mutant cells still exist. Long-term follow-up shows that some patients may relapse or develop new drug-resistant clones. Therefore, in terms of treatment strategy, ensidipine is more suitable as maintenance treatment or in combination with other drug regimens, rather than as a single drug to pursue a complete cure.

In clinical practice, some IDH2-mutated AML patients have achieved complete remission under ensidipine treatment, and their hematological indicators have returned to close to normal levels, which to a certain extent has improved the patient's quality of life and life expectancy. However, due to the complexity and polyclonal characteristics of AML, ensidipine alone cannot guarantee long-term disease-free status for all patients. Therefore, the current medical consensus believes that ensidipine is an effective targeted control drug for IDH2-mutated AML, but it cannot yet be called a radical cure.

Reference materials:https://www.idhifa.com/